PE20121523A1 - Metodo de tratamiento - Google Patents
Metodo de tratamientoInfo
- Publication number
- PE20121523A1 PE20121523A1 PE2012000913A PE2012000913A PE20121523A1 PE 20121523 A1 PE20121523 A1 PE 20121523A1 PE 2012000913 A PE2012000913 A PE 2012000913A PE 2012000913 A PE2012000913 A PE 2012000913A PE 20121523 A1 PE20121523 A1 PE 20121523A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- methyl
- treatment method
- treatment
- formulid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 abstract 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000639 pazopanib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA EL TRATAMIENTO DE UN TRASTORNO DE ANGIOGENESIS OCULAR O FILTRACION VASCULAR TAL COMO LA DEGENERACION MACULAR RELACIONADA CON LA EDAD (AMD) NEOVASCULAR, EL CUAL COMPRENDE ADMINISTRAR ORALMENTE UNA CANTIDAD DE 1MG A 50MG DE UN DERIVADO DE PIRIMIDINA DE FORMULA (I) QUE ES 5-[[4-[(2,3-DIMETIL-2H-INDAZOL-6-IL)-METIL-AMINO]-2-PIRIMIDINIL]-AMINO]-2-METIL-BENCEN-SULFONAMIDA (PAZOPANIB) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, O UN COMPUESTO DE FORMULA (II)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29274710P | 2010-01-06 | 2010-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121523A1 true PE20121523A1 (es) | 2012-12-12 |
Family
ID=44305773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000913A PE20121523A1 (es) | 2010-01-06 | 2011-01-05 | Metodo de tratamiento |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130012531A1 (es) |
| EP (1) | EP2521550A4 (es) |
| JP (1) | JP2013516472A (es) |
| KR (1) | KR20120125244A (es) |
| CN (1) | CN102781450A (es) |
| AU (1) | AU2011203706A1 (es) |
| BR (1) | BR112012016673A2 (es) |
| CA (1) | CA2786328A1 (es) |
| CL (1) | CL2012001852A1 (es) |
| CO (1) | CO6561789A2 (es) |
| DO (1) | DOP2012000174A (es) |
| EA (1) | EA201290603A1 (es) |
| IL (1) | IL220594A0 (es) |
| MA (1) | MA33991B1 (es) |
| MX (1) | MX2012007875A (es) |
| PE (1) | PE20121523A1 (es) |
| PH (1) | PH12012501358A1 (es) |
| SG (1) | SG181826A1 (es) |
| TW (1) | TW201201808A (es) |
| UY (1) | UY33164A (es) |
| WO (1) | WO2011085007A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE |
| JP2015523546A (ja) * | 2012-05-01 | 2015-08-13 | トランスレイタム メディカス インコーポレイテッド | 失明性疾患を処置および診断するための方法 |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| PT3039424T (pt) | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
| CA2957548A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| EP3302379B1 (en) | 2015-06-06 | 2023-11-22 | Cloudbreak Therapeutics, LLC | Compositions and methods for treating pterygium |
| US10323349B2 (en) * | 2015-09-25 | 2019-06-18 | Kyoudojyutaku Co., Ltd. | Washing system |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304059B6 (cs) * | 2000-12-21 | 2013-09-11 | Glaxo Group Limited | Deriváty pyrimidinu a farmaceutický prostredek |
| PL1968594T3 (pl) * | 2005-11-29 | 2011-03-31 | Glaxosmithkline Llc | Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| US8334239B2 (en) * | 2007-07-10 | 2012-12-18 | The Board Of Regents Of The University Of Texas System | High affinity VEGF-receptor antagonists |
| US20090325959A1 (en) * | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
| EP2453748A4 (en) * | 2009-07-16 | 2013-01-02 | Glaxo Wellcome Mfg Pte Ltd | METHOD OF TREATMENT |
-
2011
- 2011-01-04 TW TW100100228A patent/TW201201808A/zh unknown
- 2011-01-04 UY UY0001033164A patent/UY33164A/es not_active Application Discontinuation
- 2011-01-05 CA CA2786328A patent/CA2786328A1/en not_active Abandoned
- 2011-01-05 CN CN2011800126697A patent/CN102781450A/zh active Pending
- 2011-01-05 KR KR1020127017481A patent/KR20120125244A/ko not_active Withdrawn
- 2011-01-05 EA EA201290603A patent/EA201290603A1/ru unknown
- 2011-01-05 JP JP2012548091A patent/JP2013516472A/ja not_active Withdrawn
- 2011-01-05 MA MA35126A patent/MA33991B1/fr unknown
- 2011-01-05 SG SG2012045431A patent/SG181826A1/en unknown
- 2011-01-05 AU AU2011203706A patent/AU2011203706A1/en not_active Abandoned
- 2011-01-05 US US13/518,407 patent/US20130012531A1/en not_active Abandoned
- 2011-01-05 MX MX2012007875A patent/MX2012007875A/es not_active Application Discontinuation
- 2011-01-05 PE PE2012000913A patent/PE20121523A1/es not_active Application Discontinuation
- 2011-01-05 PH PH1/2012/501358A patent/PH12012501358A1/en unknown
- 2011-01-05 EP EP11732087.9A patent/EP2521550A4/en not_active Withdrawn
- 2011-01-05 BR BR112012016673A patent/BR112012016673A2/pt not_active IP Right Cessation
- 2011-01-05 WO PCT/US2011/020231 patent/WO2011085007A1/en not_active Ceased
-
2012
- 2012-06-19 DO DO2012000174A patent/DOP2012000174A/es unknown
- 2012-06-21 IL IL220594A patent/IL220594A0/en unknown
- 2012-07-06 CL CL2012001852A patent/CL2012001852A1/es unknown
- 2012-07-06 CO CO12113697A patent/CO6561789A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA201290603A1 (ru) | 2013-03-29 |
| MA33991B1 (fr) | 2013-02-01 |
| WO2011085007A1 (en) | 2011-07-14 |
| CA2786328A1 (en) | 2011-07-14 |
| DOP2012000174A (es) | 2012-12-15 |
| SG181826A1 (en) | 2012-07-30 |
| CO6561789A2 (es) | 2012-11-15 |
| IL220594A0 (en) | 2012-08-30 |
| UY33164A (es) | 2011-08-31 |
| EP2521550A4 (en) | 2013-07-03 |
| AU2011203706A1 (en) | 2012-07-12 |
| CN102781450A (zh) | 2012-11-14 |
| PH12012501358A1 (en) | 2019-03-22 |
| TW201201808A (en) | 2012-01-16 |
| BR112012016673A2 (pt) | 2018-06-05 |
| JP2013516472A (ja) | 2013-05-13 |
| KR20120125244A (ko) | 2012-11-14 |
| EP2521550A1 (en) | 2012-11-14 |
| US20130012531A1 (en) | 2013-01-10 |
| CL2012001852A1 (es) | 2012-11-30 |
| MX2012007875A (es) | 2012-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121523A1 (es) | Metodo de tratamiento | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| CR20140301A (es) | Derivados de betulina | |
| UY35146A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20142148A1 (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| NI201200017A (es) | Formulación farmacéutica | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| UY31824A (es) | Nuevos compuestos | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| BR112013012665A2 (pt) | composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica | |
| CO6331429A2 (es) | Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas | |
| AR092627A1 (es) | Derivados glucopiranosidos de urea | |
| MX358470B (es) | Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus. | |
| AR090959A1 (es) | Analogos de hexadepsipeptidos como compuestos anticancerigenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |